Minimally invasive simple prostatectomy in the era of laser enucleation for high-volume prostates: A systematic review and meta-analysis

Josselin Abi Chebel, Julien Sarkis, Elie El Helou, Elie Hanna, Georges Abi Tayeh and Albert Semaan

Department of Urology, Hôtel-Dieu de France Hospital, Beirut, Lebanon

ABSTRACT

Objective: To perform a systematic review and meta-analysis of available prospective and retrospective studies comparing the minimally invasive (laparoscopic or robot-assisted) simple prostatectomy (MISP) and laser enucleation of the prostate for treating male lower urinary tract symptoms in high-volume prostates, as laser enucleation of the prostate is the new trend for treating high-volume prostates (>80 mL) but many urologists now prefer MISP.

Methods: A systematic search was done using the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Cochrane databases in June 2019, with research terms including: ‘laser’, ‘laparoscopy’, ‘enucleation’, ‘BPH’, ‘simple prostatectomy’, ‘Millins’, and ‘adenomectomy’. The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Of 38 screened articles, six were analysed and a total of 975 men were included. The average operative time, length of stay and catheterisation time were significantly shorter in the laser enucleation group ($P = 0.006, P < 0.001$ and $P < 0.001$, respectively). The amount of prosthetic tissue removed during surgery was comparable between both the laser enucleation and MISP groups ($P = 0.39$). The International Prostate Symptom Score, prostate-specific antigen level, maximum urinary flow rate and post-void residual urine volume were also comparable at 3 months. Finally, similar transfusion rates and Clavien–Dindo complication rates were observed ($P = 0.08$ and $P = 0.41$, respectively).

Conclusion: This systematic review of the literature and meta-analysis provide a further demonstration of the safety and effectiveness of both laser enucleation and MISP. While laser enucleation had a shorter catheterisation time and hospital stay than MISP, the latter still had unique and specific indications.

Abbreviations: ELEP: eraser laser enucleation of the prostate; HoLEP: holmium laser laser enucleation of the prostate; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PVR: post-void residual urine volume; $Q_{\text{max}}$: maximum urinary flow rate; (L)(M)(R)SP: (laparoscopic) (minimally-invasive) (robot-assisted) simple prostatectomy

Introduction

BPH affects 70% of men aged between 60 and 69 years, and has a significant impact on a patient’s quality of life, particularly for those with moderate-to-severe LUTS with prostate volumes of >80 mL [1]. While the first-line treatment of BPH is usually medical therapy, surgical intervention is needed in refractory conditions, as well as in complicated cases (recurrent UTIs, bladder calculi, bladder diverticulum, refractory haematuria, and dilation of the upper tract) [2].

Laser endoscopic enucleation (mainly holmium laser enucleation of the prostate [HoLEP] [3], eraser laser enucleation of the prostate [ELEP] [4] and thulium vapor-enucleation of the prostate [ThuVEP] [5]) of the prostate is becoming the new trend for BPH treatment for prostates of >80 mL, with comparable results and a better safety profile than the classical open simple prostatectomy (SP) [6–9]. Nonetheless, a considerable number of urologists are relying on SP as the treatment of choice for high-volume BPH, especially with the development of minimally invasive laparoscopic and robot-assisted SP (LSP and RASP) that benefit from the same perioperative results of the open technique, but with a better safety profile [10,11].

The aim of the present study was therefore to systematically review and analyse the evidence and compare the effectiveness and safety between LSP/RASP and laser enucleation for treating male LUTS due to high-volume prostates.

Methods

To our knowledge, there is no systematic review of the literature comparing minimally invasive SP (MISP) with laser enucleation for the treatment of BPH. A systematic search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [12]. The search was
done using the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Cochrane library databases on the 23 June 2019. Specific search terms included, but were not limited to: ‘laser’, ‘laparoscopy’, ‘enucleation’, ‘BPH’, ‘simple prostatectomy’, ‘Millins’, and ‘adenomectomy’. Phrases were combined using Boolean operators (AND, OR) to augment the search.

**Data extraction and analysis**

All prospective or retrospective studies comparing laser prostate enucleation with either LSP or RASP were included in this review. We excluded non-comparative studies, reviews and comments, as well as studies that included prostates of <80 mL. The list of the potential studies was then reviewed by the authors and data were collected. The identification of relevant studies, the selection based on the criteria just described, and the subsequent data extraction were performed independently by two of the authors; conflicts were resolved by a third author. The meta-analytic software RevMan 5.3 (Cochrane, London, UK) was employed. Both random- and fixed-effects analyses were performed. The random-effects analyses were considered the lead approach, as they make fewer assumptions.

**Outcome measures**

The primary endpoints analysed were postoperative outcomes: the maximum urinary flow rate ($Q_{\text{max}}$), post-operative PSA level, post-void residual urine volume (PVR) and the IPSS. Postoperative dysuria and urinary incontinence were also reviewed. Secondary outcomes included perioperative parameters such as operative time, catheterisation time, length of stay, amount of tissue removed, blood loss, and complications according to the Clavien–Dindo classification system [13].

**Results**

In total, 38 articles were screened, from which six met our predefined inclusion criteria. Those six articles were analysed: five were retrospective trials and only one was a prospective trial. One study [14] was reviewed but was not included in the meta-analysis due to an absence of dispersion measures. The study’s PRISMA flow chart is presented in Figure 1.

**Characteristics of included studies**

All studies were conducted either in Europe or the USA, and published between 2015 and 2018. They included a total of 975 patients, of which 759 underwent laser enucleation (704 HoLEP, 20 ELEP, and 35 ThuVEP); 216 underwent MISP (68 LSP and 148 RASP). The patient demographics of both groups were comparable. All patients had a prostate volume measurement performed by a radiologist via TRUS. The surgical techniques used in the studies were either transcapsular (Millin) prostatectomy or transvesical (Freyer) prostatectomy. For HoLEP, the conventional Gilling technique was used. The summary of the pre-operative parameters for the different studies are listed in Table 1 [1,14–18].

**Perioperative endpoints**

The perioperative outcomes were available from all six studies (Figure 2). The average operative time, with a mean difference of 68.09 min ($P = 0.006$, Figure 2(c)), length of stay (mean difference of 2.52 days, $P < 0.001$, Figure 2(a)) and catheterisation time (mean difference of 3.5 days, $P < 0.001$, Figure 2(b)), was significantly shorter in the laser enucleation group when compared to MISP. The amount of prostatic tissue removed during surgery, even though higher in the MISP group, was statistically comparable ($P = 0.39$, mean difference of 10.41 g (95% CI – 13.15, 33.98); Figure 2(d)).

**Postoperative endpoints**

A 3-month follow-up was completed in four studies, with statistically comparable post-surgical outcomes (IPSS, PSA level, $Q_{\text{max}}$ and PVR) on meta-analysis (Figure 3 [14–17]). Only one study [15] continued follow-up to 6 months after surgery, with comparable IPSS (mean (SD) 4.05 (1.23) in the ELEP group vs 4.70 (0.73) in the LSP group, $P = 0.052$), but a statistically lower PVR in favour of laser enucleation (mean (SD) 33.9 (9.26) vs 44.5 (15) mL, $P = 0.011$). On the other hand, Baldini et al. [16] reported that eight of 39 (25%) patients who underwent HoLEP reported postoperative pollakiuria and urinary urgency, compared to two of 28 (7.1%) in the LSP group. Umari et al. [17] also reported that four of 45 (8.9%) patients reported transient urinary incontinence following HoLEP, while only one of 81 (1.2%) complained of transient incontinence following RASP. Only one study [15] evaluated quality of life at 3 and 6 months, showing comparable results ($P = 0.84$).

**Complications and blood loss**

There was statistically significantly higher blood loss in the MISP group ($P < 0.001$, Figure 4(b)), but without a significantly higher rate of blood transfusions ($P = 0.08$, Figure 4(a)). While Nestler et al. [18] reported
Figure 1. Study PRISMA flow chart.

Table 1. Summary of preoperative parameters.

| Patients, n | Prostate volume, mL, mean (SD) | IPSS, mean (SD) | Q\(_\text{max}\), mL/s, mean (SD) | PVR, mL, mean (SD) | PSA level, ng/ml, mean (SD) |
|------------|-------------------------------|----------------|----------------------------------|------------------|-----------------------------|
| Baldini et al. [16] | HoLEP 39 | 83.9 (179.9) | 21.1 (6.37) | 8.2 (5.2) | 137.1 (18.5) | 7.2 (4.6) |
| LSP 28 | 120.5 (197.1) | 19.8 (13.5) | 7.5 (4.7) | 159.4 (47.1) | 8.4 (7.7) |
| P \(\leq0.001\) | <0.001 | 0.607 | 0.702 | 0.675 | 0.430 |
| Juaneda et al. [14] | HoLEP 20 | 126.3 | 21 | 6.5 | – | – |
| LSP 20 | 127.5 | 23.5 | 8.9 | – | – |
| P | 0.91 | – | – | – | – |
| Lusuardi et al. [13] | ELEP 20 | 96.1 (35.9) | 28.4 (4.95) | 6.7 (2.6) | 173.7 (82.5) | 8.07 (3.7) |
| LSP 20 | 94.0 (22.4) | 27.7 (4.96) | 7.8 (2.27) | 142.5 (69.6) | 7.5 (3.3) |
| P | 0.83 | 0.64 | 0.18 | 0.2 | 0.61 |
| Nestler et al.* [18] | ThuVEP 35 | 95.2 (37.1) | 20.4 (3.9) | – | – | – |
| RASP 35 | 104.8 (41.8) | 22.6 (3.9) | – | – | – |
| P | 0.41 | 0.5 | – | – | – |
| Umari et al.* [17] | HoLEP 45 | 131.1 (28.3) | 19.9 (6.9) | 8.6 (5.3) | 107.4 (98.8) | 9.7 (8.6) |
| RASP 81 | 144.4 (59.6) | 24.2 (6.0) | 8 (4.5) | 75.8 (43.7) | 8.1 (6.3) |
| P | 0.06 | 0.05 | 0.5 | 0.2 | 0.6 |
| Zhang et al. [1] | HoLEP 600 | – | 20 (7) | – | – | – |
| RASP 32 | – | 24 (4) | – | – | – |
| P | – | 0.21 | – | – | – |

*Median values presented in Nestler et al. and Umari et al. were converted to mean ± SD (Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805).
A lower complication rate in the ThuVEP group when compared to MISP (one of 35 vs nine of 35), analysis of Clavien–Dindo complications of Grade ≥3 showed comparable results between the laser enucleation and MISP groups ($P = 0.41$, Figure 4(c)).

**Discussion**

With recent technical developments in laser technology, endoscopic enucleation of the prostate and SP have both become the ‘gold standard’ for surgical therapy of high-volume BPH [19]. At the same time, LSP and RASP (MISP) are overcoming the more classical open approach, mainly due to their better safety profile. However, even in the era of minimally invasive surgery, few studies exist comparing MISP with endoscopic enucleation of the prostate. We therefore performed the present systematic review of the literature with subsequent meta-analysis to better judge these two procedures. We found that MISP (either LSP or RASP) and enucleation of the prostate are equally efficient in terms of postoperative $Q_{\text{max}}$, PVR and IPSS, therefore showing similar impact on relieving the BOO. This is added to the fact that both techniques resected statistically comparable amounts of prostatic tissue. Additionally, both surgeries appear to have few postoperative complications ($11/680$ Clavien–Dindo Grade ≥2 complications in the laser enucleation group and $10/148$ in the MISP group, $P = 0.41$), making them safe procedures when performed by expert surgeons. And although haemoglobin loss was statistically higher in the MISP group, it did not translate to

---

### Table A. Length of stay (days)

| Study or Subgroup | Laser Enucleation | MISP | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-------------------|------|-----------------------------------|-----------------------------------|
| Lusuardi 2014     | 2.6               | 0.88 | 20                                | 7.8                               |
| Nestler 2018      | 2.3               | 0.78 | 35                                | 5.3                               |
| Umarri 2016       | 2                | 0.001 | 45                              | 1.5                               |
| Baldini 2017      | 2.8               | 3.2  | 39                                | 4.0                               |
| Zhang 2017        | 1.3               | 1    | 600                               | 2.3                               |
| Juanteda 2015     | 1                 | 0    | 20                                | 4.9                               |

Total (95% CI): 759 216 100.0% -2.52 [-3.90, -1.13]

Heterogeneity: $\tau^2 = 2.36; \chi^2 = 162.41; df = 4 (P < 0.00001); \phi = 98$

Test for overall effect: $Z = 3.56 (P = 0.0004)$

### Table B. Catheterisation time (days)

| Study or Subgroup | Laser Enucleation | MISP | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-------------------|------|-----------------------------------|-----------------------------------|
| Zhang 2017        | 0.7               | 0.4  | 600                               | 8                                 |
| Lusuardi 2014     | 2.5               | 0.88 | 20                                | 7.2                               |
| Nestler 2018      | 2.3               | 0.78 | 35                                | 5.0                               |
| Umarri 2016       | 1.9               | 1.8  | 39                                | 3.7                               |
| Baldini 2017      | 2.0               | 0.001 | 45                             | 3.1                               |
| Juanteda 2015     | 1.86              | 0    | 0                                 | 3.65                              |

Total (95% CI): 759 216 100.0% -3.50 [-5.32, -1.69]

Heterogeneity: $\tau^2 = 4.19; \chi^2 = 348.95; df = 4 (P < 0.00001); \phi = 99$

Test for overall effect: $Z = 3.78 (P = 0.0002)$

### Table C. Operative time (min)

| Study or Subgroup | Laser Enucleation | MISP | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-------------------|------|-----------------------------------|-----------------------------------|
| Zhang 2017        | 103               | 47   | 600                               | 274                               |
| Nestler 2018      | 82.6              | 34.78 | 35                             | 180.57                            |
| Lusuardi 2014     | 78.4              | 10   | 20                                | 138.8                             |
| Baldini 2017      | 106.6             | 41.903 | 39                             | 115                               |
| Umarri 2016       | 110.3             | 14.46 | 45                             | 113.81                            |
| Juanteda 2015     | 125               | 0    | 20                                | 109                               |

Total (95% CI): 759 196 100.0% -68.09 [-116.68, -19.30]

Heterogeneity: $\tau^2 = 3041.34; \chi^2 = 272.51; df = 4 (P < 0.00001); \phi = 99$

Test for overall effect: $Z = 4.74 (P = 0.006)$

### Table D. Prostatic tissue removed during surgery (g)

| Study or Subgroup | Laser Enucleation | MISP | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|-------------------|------|-----------------------------------|-----------------------------------|
| Umarri 2016       | 93.25             | 39.25 | 81                             | 117.31                            |
| Nestler 2018      | 83.4              | 52.56 | 35                             | 78.4                              |
| Baldini 2017      | 81.1              | 36.08 | 28                             | 52.4                              |
| Lusuardi 2014     | 87.0              | 22.4  | 45                             | 58.5                              |

Total (95% CI): 215 759 100.0% 10.41 [-13.15, 33.98]

Heterogeneity: $\tau^2 = 653.77; \chi^2 = 47.52; df = 4 (P < 0.00001); \phi = 92$

Test for overall effect: $Z = 0.67 (P = 0.39)$
Table 1. Follow-up at 3 months. Forrest plot comparing IPSS at 3 months after surgery indicates no statistical difference between both groups. Meta-analysis of remaining outcomes showed comparable postoperative $Q_{\text{max}}$ [mean difference $-0.17\,\text{mL/s (95\% CI} \, -0.35, -0.00)$], PSA level [mean difference $0.17\,\text{ng/mL (95\% CI} \, -0.20, 0.53)$] and PVR [mean difference $-3.73\,\text{mL (95\% CI} \, -10.18, 2.71)$] *Median values presented in Umari et al. were converted to mean ± SD (Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–1805). a higher transfusion rate (probably explained by the pneumoperitoneum effect in preventing major venous bleeding during laparoscopic or robotic interventions). It should be noted, however, that two studies reported higher postoperative dysuria and incontinence rates in the laser enucleation group.

The main differences found between the two techniques concerned the perioperative outcomes: patients undergoing laser enucleation of the prostate had a shorter operative time and Foley catheterisation time, and were consequently discharged sooner from hospital.

Despite the advantages of laser enucleation, MISP is preferable for specific indications: a very interesting indication for LSP or RASP is the concomitant treatment of bladder diverticulum or bladder stone [20]. These cases are rarely treated via a transurethral approach, as large bladder stones would add a significant operative time if treated with laser techniques.

In addition, while both techniques have learning difficulties in common [16], RASP could be considered an interesting option for surgeons who have completed the learning curve by performing an adequate number of robot-assisted radical prostatectomies. In comparison, surgeries that involve laser enucleation of the prostate, e.g. the HoLEP technique, have a long learning curve with variability in performance, even for a surgeon with extensive experience [21,22].

A further issue that needs assessment is the financial aspect of both procedures. For instance, Juaneda et al. [14] evaluated the separate cost of HoLEP and LSP, with a mean cost of €2871 (Euros) for HoLEP and €4706 for LSP. This difference is mainly due to the fact that the hospital stay is much shorter when using the HoLEP technique. In a hospital where laparoscopy is available and in low-volume centres that cannot afford the expenses of a new holmium generator, LSP may be more affordable than HoLEP. More studies assessing real data and cost analysis (capital costs of equipment, hospital stay and care costs, complications and operative time) are needed.
Strengths and limitations

This is the first literature review comparing LSP or RASP with laser enucleation, mainly HoLEP; the review is strengthened by its systematic approach. Another positive attribute is the large number of patients included (975). The main limitation is the small number of studies included, and the retrospective design of most of them. Furthermore, sexual function is an important patient-related outcome that was not assessed in the analysed studies. The variability of laser enucleation arms across the studies (LSP, RASP, HoLEP, ELEP, ThuVEP) made the comparison uneven. Further prospective randomised studies are needed to fully identify any significant difference among all of the techniques.

Conclusion

For men requiring a surgical treatment for their BPH with large-volume prostates of >80 mL, MISP and laser enucleation both appear to be effective and safe procedures. While laser enucleation showed a better perioperative profile, such as shorter catheterisation time and hospital stay compared with that of MISP, the latter has specific indications when bladder diverticulum or stones are present. These results can help physicians choose the best surgical approach for patients with high-volume BPH.

Finally, more prospective randomised studies, as well as meta-analyses comparing MISP and laser enucleation, are necessary to define the standard surgical treatment for large prostates.

Acknowledgments

The work has been reported in line with the PRISMA guidelines.

Disclosure statement

No potential conflict of interest relevant to this article was reported.

ORCID

Julien Sarkis http://orcid.org/0000-0002-5060-0819
References

[1] Zhang MW, El Tayeb MM, Borofsky MS, et al. Comparison of perioperative outcomes between holmium laser enucleation of the prostate and robot-assisted simple prostatectomy. J Endourol. 2017;31:847–850.

[2] Gravas S, Cornu JN, Drake MJ, et al. EAU guidelines management of non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology, 2018 [cited 2020 Jun]. Available at: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-neurogenic-Male-LUTS-2018-large-text.pdf

[3] Cynk M. Holmium laser enucleation of the prostate: a review of the clinical trial evidence. Ther Adv Urol. 2014;6:62–73.

[4] Hruby S, Sieberer M, Schätz T, et al. Eraser laser enucleation of the prostate: technique and results. Eur Urol. 2013;63:341–346.

[5] Becker B, Herrmann TR, Gross AJ, et al. Thulium vaporization of the prostate versus holmium laser enucleation of the prostate for the treatment of large volume prostates: preliminary 6-month safety and efficacy results of a prospective randomized trial. World J Urol. 2018;36:1663–1671.

[6] Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol. 2006;50:563–568.

[7] Patel MN, Hemal AK. Robot-assisted laparoscopic simple anatomic prostatectomy. Urol Clin North Am. 2014;41:485–492.

[8] Skolarikos A, Papachristou C, Athanasiadis G, et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol. 2008;22:2333–2340.

[9] Ou R, Deng X, Yang W, et al. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study. BJU Int. 2013;112:239–245.

[10] Autorino R, Zargar H, Mariano MB, et al. Perioperative outcomes of robotic and laparoscopic simple prostatectomy: a European-American multi-institutional analysis. Eur Urol. 2015;68:86–94.

[11] Pokorny M, Novara G, Geurts N, et al. Robot-assisted simple prostatectomy for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: surgical technique and outcomes in a high-volume robotic centre. Eur Urol. 2015;68:451–457.

[12] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

[13] Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196.

[14] Juaneda R, Thanigasalam R, Rizk J, et al. Holmium laser enucleation versus laparoscopic simple prostatectomy for large adenomas. Actas Urol Esp. 2016;40:43–48.

[15] LuSaundi L, Hruby S, Janetschek G, et al. Laparoscopic adenomectomy versus Eraser laser enucleation of the prostate. World J Urol. 2015;33:691–696.

[16] Baldini A, Fassi-Fehri H, Duarte RC, et al. Holmium laser enucleation of the prostate versus laparoscopic transcapsular prostatectomy: perioperative results and three-month follow-up. Curr Urol. 2017;10:81–86.

[17] Umari P, Fossati N, Gandaglia G, et al. Robotic assisted simple prostatectomy versus holmium laser enucleation of the prostate for lower urinary tract symptoms in patients with large volume prostate: a comparative analysis from a high volume center. J Urol. 2017;197:1108–1114.

[18] Nestler S, Bach T, Herrmann T, et al. Surgical treatment of large volume prostates: a matched pair analysis comparing the open, endoscopic (ThuVep) and robotic approach. World J Urol. 2019;37:1927–1931.

[19] Foster HE, Dahm P, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202:592–598.

[20] Magera JS, Adam CM and Igor F. Robot-assisted laparoscopic transvesical diverticulectomy and simple prostatectomy. J Robot Surg. 2008;2:205–208.

[21] Gupta NP, Nayyar R. Management of large prostatic adenoma: lasers versus bipolar transurethral resection of prostate. Indian J Urol. 2013;29:225–235.

[22] Haraguchi T, Takenaka A, Yamazaki T, et al. The relationship between the reproducibility of holmium laser enucleation of the prostate and prostate size over the learning curve. Prostate Cancer Prostatic Dis. 2009;12:281–284.